Related Experiment Videos

Status of umbilical cord blood transplantation in the year 2001

J M Hows1

  • 1Division of Transplantation Sciences, Blue Zone A, Entrance 11, Southmead Health Services, University of Bristol, Westbury on Trym, Bristol BS10 5NB, UK. jill.hows@bristol.ac.uk

Insights

Umbilical cord blood (UCB) transplantation offers reduced graft-versus-host disease compared to bone marrow. However, UCB use is limited by cell dose, primarily benefiting smaller patients and ethnic minorities.

Area of Science:

  • Hematology
  • Transplantation Immunology
  • Pediatric Oncology

Background:

  • Umbilical cord blood (UCB) transplantation is a valuable alternative to bone marrow transplantation.
  • Current limitations in UCB transplantation include the low hematopoietic cell dose, restricting its use primarily to smaller recipients.
  • Ethnic minority children may particularly benefit from UCB transplantation due to donor matching challenges.

Purpose of the Study:

  • To review the current status and tentative recommendations for umbilical cord blood transplantation.
  • To compare UCB transplantation with bone marrow transplantation regarding graft-versus-host disease and leukemic relapse.
  • To outline criteria for UCB collection and patient selection.

Main Methods:

  • Retrospective analysis of cohort-controlled data comparing UCB and bone marrow transplantation.
  • Review of existing literature and clinical observations regarding UCB transplantation outcomes.
  • Formulation of tentative recommendations based on current evidence.

Main Results:

  • UCB transplantation from HLA-identical siblings shows significantly less acute and chronic graft-versus-host disease compared to sibling marrow.
  • Data on graft-versus-host disease in unrelated donor UCB transplantation are pending.
  • The difference in leukemic relapse rates between UCB and bone marrow transplantation is currently unknown.

Conclusions:

  • UCB collection is indicated for healthy newborn siblings when urgent transplantation is needed for an older child.
  • Antenatal fetal HLA typing is not recommended.
  • UCB should be considered for pediatric patients lacking an HLA-identical sibling or a well-matched unrelated adult donor, with a minimum nucleated cell dose of 2 x 10(7)/kg.

Related Concept Videos